Ribonuclease M2: Potential Drug Target and Biomarker for Diseases

Target Name: Mitochondrial RNA processing endoribonuclease

NCBI ID: P16334

Mitochondrial RNA processing endoribonuclease

Other Name(s): Ribonuclease mitochondrial RNA processing | RNase MRP

Ribonuclease M2: Potential Drug Target and Biomarker for Diseases

Mitochondrial RNA processing endoribonuclease (Ribonuclease mitochondrial RNA processing), also known as ribonuclease M2, is a protein that plays a crucial role in the processing of mitochondrial RNA (mRNA) during the translation of gene information from DNA to RNA. Ribonuclease M2 is a member of the RNA processing machinery and is located in the mitochondria, where it helps to remove non-coding regions from the pre-mRNA that are not required for protein synthesis.

Ribonuclease M2 is a protein that contains 115 amino acids and has a calculated molecular weight of 13.9 kDa. It has a characteristic Rossmann-fold structure that is composed of a parallel beta-sheet and a distinct alpha-helices. The protein has a single subunit, and its function is to process the 5' end of pre-mRNA and remove non-coding regions.

The ribonuclease M2 protein has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and genetic disorders. Its role in the processing of mitochondrial RNA has also been implicated in the pathogenesis of various diseases, including neurodegenerative diseases.

One of the key functions of Ribonuclease M2 is its ability to remove non-coding regions from the pre-mRNA that are not required for protein synthesis. This process is known as 3' endonuclease activity, and it allows the ribonuclease M2 protein to specifically target and remove non-coding regions from the pre-mRNA that are not necessary for protein synthesis.

The ribonuclease M2 protein has been shown to play a role in the regulation of gene expression in various organisms, including bacteria and eukaryotes. For example, studies have shown that the ribonuclease M2 protein can inhibit the translation of certain mRNAs, and that it can also enhance the translation of other mRNAs.

In addition to its role in the regulation of gene expression, the ribonuclease M2 protein has also been shown to play a role in the processing of mitochondrial RNA. Studies have shown that the ribonuclease M2 protein can process the 5' end of pre-mRNA and remove non-coding regions, which is consistent with its function as a 3' endonuclease.

The ribonuclease M2 protein is also known to have been involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and genetic disorders. For example, studies have shown that the ribonuclease M2 protein is overexpressed in various diseases, including cancer, and that this overexpression can contribute to the development and progression of these diseases.

In addition to its involvement in the regulation of gene expression and the processing of mitochondrial RNA, the ribonuclease M2 protein has also been implicated in the pathogenesis of various diseases. For example, studies have shown that the ribonuclease M2 protein is overexpressed in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

The ribonuclease M2 protein is also a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and genetic disorders. For example, studies have shown that the ribonuclease M2 protein can be used as a biomarker for cancer, and that this biomarker can be sensitive to changes in the levels of the protein in cancer cells.

In conclusion, the ribonuclease M2 protein is a protein that plays a crucial role in the processing of mitochondrial RNA during the translation of gene information from DNA to RNA. It is a potential drug target and

Protein Name: Mitochondrial RNA Processing Endoribonuclease

The "Mitochondrial RNA processing endoribonuclease Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Mitochondrial RNA processing endoribonuclease comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets